To provide more compelling evidence for the clinical applicability of blood‐based biomarkers in AD, we primarily aimed to investigate the evolutionary patterns of these plasma biomarkers throughout the course of AD, assess the diagnostic accuracy of plasma p‐tau217 in distinguishing between various Aβ/tau stages, substantiate the role of plasma GFAP in the Aβ‐induced propagation of tau pathology across Braak stages, and examine the involvement of plasma NfL in AD‐associated hippocampal atrophy and cognitive deterioration. The gene discussed is MAPT; the disease is hippocampal atrophy.